top of page

Ipsen’s kidney cancer drug receives positive CHMP and ‘Promising Innovative Medicine’ status

Ipsen announced today that the Committee for Medicinal Products for human use (CHMP), the scientific committee of the European Medicines Agency (EMA), has provided a positive opinion for Cabometyx (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page